How does ticagrelor affect rosuvastatin exposure and the risk of muscle injury?

Ticagrelor increases rosuvastatin Cmax approximately 2.5-fold and AUC approximately 2.4-fold, potentially increasing myopathy risk, including rhabdomyolysis, so rosuvastatin’s cardiovascular benefits should be weighed against the risks of increased plasma concentrations.